A Study to Evaluate GFH375 Versus Docetaxel in Participants With Non-Small Cell Lung Cancer With KRAS G12D Mutation

Exclusion Criteria

• •1\. Presence of other driver gene mutations in NSCLC, or concurrent other KRAS or RAS mutations.
• •2\. Other malignancy that has progressed or required treatment within 3 years prior to randomization.
• •3\. Leptomeningeal metastasis, or symptomatic or progressive central nervous system (CNS) metastasis.
• •4\. Existing or potential severe bone injury due to bone metastasis, or uncontrolled pain related to bone metastasis.
• •5\. Prior treatment with KRAS G12D targeted therapy or pan RAS/KRAS targeted therapy.
• •6\. Prior treatment with docetaxel as part of systemic therapy.
• •7\. Radiotherapy within 4 weeks prior to randomization, or other local anti tumor therapy within 4 weeks prior to randomization.
• •8\. Other anti tumor therapy within 28 days or 5 half lives prior to randomization, or cell therapy within 3 months prior to randomization.
• •9\. Clinically significant severe cardiovascular disease.
• •10\. Stroke or other severe cerebrovascular disease within 6 months prior to randomization.
• •11\. Major acute or chronic infectious disease.
• •12\. Other poorly controlled systemic diseases.
• •13\. Severe psychiatric or psychological disorder, or history of drug abuse, or severe alcohol abuse.
• •14\. Pregnancy or breastfeeding.
• •15\. Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.